What is Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?
CATEGORY:
Bortezomib-cyclophosphamide-dexamethasone, also known as VCd or CyBorD, is a regimen that may be used for the treatment of multiple myeloma. It contains the anticancer agents bortezomib and cyclophosphamide along with dexamethasone, a corticosteroid.
Save up to 80% off your prescriptions!
How do members experience Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?
Top 5 reported purposes & perceived effectiveness
Purpose | Patients | Evaluations | Perceived Effectiveness |
---|---|---|---|
Multiple myeloma | 454 | 38 |
Common side effects
Side effect | Patients | Percentage |
---|---|---|
Fatigue | 5 | |
Peripheral neuropathy | 5 | |
Constant tiredness | 2 | |
Numbness | 2 | |
Tiredness | 2 | |
Bone pain | 1 |
Side effect severity
Severity | Evaluations | Percentage |
---|---|---|
Severe | 9 | |
Moderate | 16 | |
Mild | 9 | |
None | 4 |
Member evaluations
annswanson
evaluated on Sep 03, 2015
- Perceived effectiveness for multiple myeloma: Major
- Side effects: Moderate
Learn more about our community’s experience with Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)
What are people saying about Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?
479
479
members have reported taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)
Join the conversation and connect with people who have taken Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)
Last updated: